Exploring long-term responses to immune checkpoint inhibitors in recurrent and metastatic head and neck squamous cell carcinomaMichel Bila, Paul M. Clément, Jeroen Meulemans et al.|Oral Oncology|2023Cited by 13
Impact of time-of-day administration of immune checkpoint inhibitors on survival outcomes in patients with recurrent/metastatic head and neck cancer (R/M HNSCC): a retrospective cohort studyPaulien Van Loocke, Paul M. Clément, Benoit Beuselinck et al.|Oral Oncology|2025Cited by 3